BridgeBio Oncology Therapeutics (BBOT) Accumulated Expenses (2023 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Accumulated Expenses of $2.0 million for Q1 2026, down 64.88% sequentially from $5.7 million in Q4 2025, and up 13.14% YoY from $1.8 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Accumulated Expenses (2023 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Accumulated Expenses for 4 years, with the latest figure at $2.0 million in Q1 2026.
- Quarterly Accumulated Expenses rose 13.14% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 13.14% YoY) and the FY2025 annual result came in at $5.7 million, up 50.38% from the prior year.
- Accumulated Expenses retreated to $2.0 million in Q1 2026 per BBOT's latest filing, from $5.7 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $5.7 million in Q4 2025 and troughed at $15000.0 in Q4 2023.
- A 4-year average of $2.0 million and a median of $1.8 million in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2026: Accumulated Expenses surged 25373.33% in 2024, then increased 13.14% in 2026.
- Over 4 years, Accumulated Expenses stood at $15000.0 in 2023, then soared by 25373.33% to $3.8 million in 2024, then surged by 50.38% to $5.7 million in 2025, then slumped by 64.88% to $2.0 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $2.0 million, $5.7 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.39 Mn |
| Mar 31, 2026 | 2.02 Mn |
| Dec 31, 2025 | 5.75 Mn |
| Sep 30, 2025 | 4.49 Mn |
| Mar 31, 2025 | 1.78 Mn |
| Dec 31, 2024 | 3.82 Mn |
| Sep 30, 2024 | 126,690.00 |
| Jun 30, 2024 | 79,141.00 |
| Mar 31, 2024 | 23,333.00 |
| Dec 31, 2023 | 15,000.00 |